FDA approves fitusiran for hemophilia A, B patients aged 12 years and up
5 pediatric FDA decisions to watch for in Q2 2025
Remestemcel-L now available to treat steroid-refractory acute graft-versus-host disease
Peter Lio, MD, highlights recent lebrikizumab data to treat atopic dermatitis